Audit: QRS - Disodium Succinoyl Farnesylcysteine for Skin Rejuvenation
Audit conducted on 11/08/2026 01:12 using AI4L + evidence-mcp / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to ER Therapeutic Protocol (lines 263–271), time cells to ER lines 137, 316, benefits to ER lines 129–163, risks to ER lines 185–203, gates to ER lines 221–243, monitoring to ER lines 342–359. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No established target” carried verbatim into marker_1_target and marker_2_target; “Nothing meaningful should be expected before then” mirrors ER line 316. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy/breastfeeding remains a Contraindication, not a caution; speculative benefits and risks stay in the Speculative tier. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from ER Benefit-Modifying Factors (lines 168–178) or Risk-Modifying Factors (lines 208–216) appears in the gates or risk card. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, DOIs, author names, or NCT IDs anywhere; “SIG-1273 products” and “tetramethylhexadecenyl succinoyl cysteine” appear in the ER interaction bullet at line 231. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Reserved, sponsor-bias-aware framing of the ER is retained (“The manufacturer designed, funded, and published essentially every result”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Concrete timepoints, targets, and cadence give the reader actionable structure without hype. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No imperatives; observations are stated in the third person. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Gates and markers are stated as evidence, not instructions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise”, or “should” outside the ER’s own verbatim expectation statement. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms appear only where the ER’s decision gates require precision, with plain glosses where possible. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | All gate and tier items are stripped to the key fact. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text search for “you”/”your”: no matches. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Monitoring instrumentation (corneometry, TEWL, erythema index) assumes a proactive, measurement-driven reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twice-daily application, staged introduction, and a 12-week measurement schedule are presented without softening. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content assumes standardized photography and handheld probe readings. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The sponsor-only evidence base is surfaced in At-A-Glance, which is the decision-relevant discriminator for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The phrase “anti-aging” does not appear; the header uses “Skin Rejuvenation”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Application-site irritation”, “transepidermal water loss”, “stratum corneum hydration”; consumer terms in the qualitative list are carried verbatim from ER lines 355–359. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All present verbatim at lines 446, 492, 541, 568, 589, 614, 633, 637–639, 740; tier labels “Medium”, “Low”, “Speculative” at lines 546, 552, 558, 619, 623. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 57 data-qrs-var spans present, forming a complete, gap-free set (page_title through qualitative_item_5) with no missing index in any numbered series. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable spans website="evidence_review", website="audit", and website="full_review" (lines 423, 426, 440) are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section drawn on by the QRS is empty; absent benefit/risk tiers are governed by 12.5 and 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Studied concentration and frequency”, “Best time of day”, “Finished-product reality” match ER lines 263, 271, 265; all eight interaction items reuse the ER bold labels from lines 221–235. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels are ER-sourced; monitoring row labels match the ER biomarker table (lines 346–351). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text Unicode scan returns no emoji; the ER’s 🟩/🟥/🟨 tier markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its budget: gates carry key facts only, benefit/risk tiers are merged into one line per tier, and the sheet defines an A4 @page rule with 12 mm padding. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the descriptive text at line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is echoed into a rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: disodium_succinoyl_farnesylcysteine_skin_2026-0810-2354_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0811-0054. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All eight remaining values are bare and trimmed. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Disodium Succinoyl Farnesylcysteine for Skin Rejuvenation - Quick Reference Sheet”; no characters require entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches ER frontmatter canonical_topic (ER line 8) exactly. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/11/2026” from qrs_creation_date: 2026-0811-0054. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the standard subline; the ER’s “Also known as” line (ER line 30) is correctly omitted. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER lines 381–387: mechanism, human results, and the sponsor-only evidence base. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Mechanism → ER line 381; results and tolerance → ER line 383; sponsor and non-replication → ER line 385. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “fatty anchor”, “signal-carrying proteins”, “cell membranes”, “inflammatory messaging” are plain-language renderings. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages or statistics; the ER’s magnitudes (32%, 42%, 52%) are excluded. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from “Populations who should avoid Disodium Succinoyl Farnesylcysteine”, ER lines 237–243. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER populations are represented, with none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements, lines 571–584. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale is stripped (“where no exposure, absorption, or reproductive data exist”, “an age group absent from every published study”); no dash-trailed clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(impetigo, active herpes simplex, scratched-open skin)” and “(Investigator Global Assessment grade 3 or 4)” retained, as are “until re-epithelialized” and “as a substitute for prescription therapy”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER contraindication bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does name such populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from ER lines 221–235. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interaction bullets are present; none duplicates a Contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements, lines 592–604. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “Caution.”/”Monitor.” verdicts and mechanistic sentences are all stripped; only the bold labels remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every drug list is preserved, including “(L-ascorbic acid at pH below 3.5)” and “(fractional laser, microneedling, chemical peels)”; only the lay gloss “immune-calming creams” is trimmed, with both named drugs kept. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does name such interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Sourced from ER Therapeutic Protocol, lines 263–271. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Studied concentration/frequency, best time of day, and finished-product reality are the three bullets that determine what is actually applied. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol lists twelve bullets, well above three. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action spans (lines 450–487) carry ER-derived content; none is empty. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Facial wrinkles (week 8), skin hydration (week 8), and facial redness (week 4), drawn from ER lines 316, 137, 145. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Wrinkles and hydration are the two Medium-tier benefits, in the ER’s own order, followed by the Low-tier redness benefit. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans (lines 498–532) are populated; subs paraphrase ER lines 316 and 137 closely. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet at line 316. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Sourced from ER lines 125–163. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 543, 544, 550, 556. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a single line of ER benefit headings; the ER’s Magnitude lines and trial descriptions are excluded. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High-tier benefit; benefits_high is empty with style="display: none" at line 543. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Sourced from ER lines 181–203. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 616, 617, 618, 621. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The HRIPT details, magnitudes, and mechanistic citations from ER lines 187–199 are all excluded. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High- or Medium-tier risk; both spans are empty with style="display: none" at lines 616–617. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from ER Monitoring Protocol & Defining Success, lines 338–351. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six ER biomarker table rows (ER lines 346–351) appear as marker_1 through marker_6, with targets and rationales preserved. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 732 reproduces ER line 342: weeks 1 and 4 for tolerance, weeks 8 and 12 for appearance, then every 3–6 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the “Qualitative markers worth tracking” list, ER lines 353–359. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers appear verbatim as qualitative_item_1 through qualitative_item_5. |
Issues 11/08/2026 01:12
Pass rate 100.00%. No issues found.
Issues 11/08/2026 01:06
- 1.1 — Contraindication paraphrases ER wording: The second stop item (line 577) renders the ER’s “scratched-open skin” as “open scratches” and drops the ER’s gloss “a bacterial skin infection” for impetigo, so the item is not a literal condensation of ER line 240.
- 4.5 — One-page budget exceeded: The Monitoring “Why” cells and marker labels (lines 656–658, 686–689, 700–702, 715–718, 728–731) and the three Protocol subs (lines 456–459, 484–487, 530–533) carry full ER sentences rather than condensed phrases, pushing the sheet beyond a single A4 page.
Fixes 11/08/2026 01:06
- 1.1 — Contraindication wording aligned to ER: Changed the second stop item from “open scratches” to the ER’s own “scratched-open skin”, so the item is a literal condensation of ER line 240.
- 4.5 — Monitoring cells condensed: Shortened marker_1_target, marker_1_why, marker_2_name, marker_2_target, marker_2_why, marker_3_why, marker_5_why, marker_6_why, and monitoring_cadence to single-clause phrases, removing roughly one wrapped line from each affected table row.
- 4.5 — Protocol and Time-to-effect subs condensed: Trimmed action_1_sub, action_2_sub, action_3_sub, and time_3_sub (e.g., “the rosacea pilot used 3% gel twice daily for 4 weeks” to “the rosacea pilot used 3% for 4 weeks”) to fit the per-cell one-page budget.
Issues 11/08/2026 00:57
- 1.1 — Week-8 timing overreaches ER: [time_1_label] “Wrinkles, texture, radiance” is paired with “Week 8”, but the ER dates only wrinkle grading to week 8 and reports radiance at week 12 (
Expected Benefits, “radiance improved about 52% at week 12”). - 1.2 — Dropped “No established target” hedge: [marker_1_target] and [marker_2_target] omit the ER Monitoring table’s cautious “No established target; track …” phrasing, presenting the tracked changes as established targets.
Fixes 11/08/2026 00:57
- 1.1 — Week-8 timing scope narrowed: Changed [time_1_label] from “Wrinkles, texture, radiance” to “Facial wrinkles”, so the “Week 8” value matches the only endpoint the ER dates to week 8.
- 1.2 — Restored “No established target” hedge: Prefixed [marker_1_target] and [marker_2_target] with “No established target;”, matching the ER Monitoring table’s cautious phrasing.